Several experimental treatments for Ebola are currently available and although none have been officially tested and approved several promising results have been observed.

Experimental Ebola Drugs

By Chandres (Own work) [CC-BY-3.0 (], via Wikimedia Commons


An experimental anti-viral drug that has shown some initial potential for the treatment of Ebola. The drug is currently in phase 3 human trials for the treatment of cytomegalovirus, adenovirus, and smallpox. An urgent authorization has been provided by the FDA for testing as a treatment for Ebola. The drug was tested with the first American case of Ebola. The patient died 4 days after receiving the drug.


Traditionally used as a treatment for HIV and Hepatitis B, it acts as a nucleoside analog reverse transcriptase inhibitor. The drug was tested by Dr. Gobee Logan in Liberia as an off label treatment for Ebola. The doctor claims significant improvement in the survival chance of patients upon receiving the medication. No official experiments have been conducted to confirm the efficacy of treatment and fears have been raised around the potential damage to the liver of a patient.


This drug has been placed on a suspended hold after phase one clinical trials resulted in flu like symptoms among test subjects. The drugĀ  is a combination of Small interfering RNAs. Three of the seven proteins present in the Ebola virus are targeted by the drug. Experimental administration of the drug is permitted in patients already infected with Ebola however healthy individuals may not receive the treatment at this time.


ZMapp is notably the best known potential Ebola treatment having been administered to several patients who survived Ebola infection. The drug is in limited supply as it is grown in a genetically modified tobacco plant and cannot be synthesized in a laboratory. In one example of testing 3 Liberians received the drug with two surviving. Supply of the medication is currently exhausted according to the manufacturer however several governments around the world have limited supplies of the drug. ZMapp contains neutralizing antibodies that allegedly provide passive immunity to the Ebola Virus.